在阿尔茨海默氏症的内分类素系统:一个网络的元分析
Yu Liu1, Hang Xing2, Yan Zhang3
1Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Journal of neuroscience research
|September 9, 2024
概括
这项研究发现,在阿尔茨海默氏病 (AD) 中,大麻素受体1 (CB1R) 降低,2-阿拉基多诺伊尔甘油醇 (2-AG) 增加. 这些内分泌系统 (ECS) 的变化表明了AD管理的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 内分泌大麻素系统 (ECS) 在神经功能中发挥作用.
- 此前对阿尔茨海默病 (AD) 中ECS变化的研究已经产生了不一致的结果.
- 了解这些变化对于开发新的AD疗法至关重要.
研究的目的:
- 综合总结和分析阿尔茨海默病 (AD) 中ECS的变化.
- 在AD中研究大麻素受体 (CB1R,CB2R),内分泌素 (2-AG,AEA) 和相关酶 (FAAH,MAGL) 的变化.
- 为了澄清ECS在AD病变发生过程中的作用.
主要方法:
- 在六个数据库中进行系统的文献搜索,寻找AD中ECS组件的研究.
- 传统的元分析来评估ECS组件的表达水平.
- 基于方法 (西区斑块,HPLC) 和大脑区域 (额叶皮层) 的子组分析.
- 网络元分析以对AD中ECS变化的程度进行排名.
主要成果:
- 传统的元分析显示,在AD患者和对照人群之间,ECS组件的总体显著差异没有.
- 亚组分析显示,在阿尔茨海默氏症中CB1R表达显著降低,特别是在西部斑块和额叶皮层研究中.
- 在HPLC小组分析中,AD患者的2-AG水平显著更高.
- 网络元分析发现2-AG和MAGL增长最大,CB1R降低最大.
结论:
- 阿尔茨海默病患者可能表现出CB1R降低和2-AG和MAGL表达增加.
- 这些发现突显了对AD管理中ECS调节的潜在治疗价值.
- 对ECS目标的进一步研究可能会导致新的AD治疗策略.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.这是一种内分泌大麻素 (endocannabinoid).网络元分析 网络元分析神经退行性疾病神经退行性疾病治疗疗法治疗疗法治疗疗法1型大麻素受体受体1型大麻素受体更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
983
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
7.9K
相关概念视频
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Role of Neurotransmitters in Memory
482
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
482
